KMT2A and acute lymphoblastic leukemia: CD22 is a B-lineage differentiation antigen that has emerged as an appealing therapeutic target in cases of r/r ALL, as it is expressed on more than 90% of leukemic cells in pediatric patients with relapsed B-ALL but not in cases with MLL rearrangements [15,16].